AGREE Reporting Checklist 2016 This Checklist Is Intended .

3y ago
204.46 KB
5 Pages
Last View : 5d ago
Last Download : 5m ago
Upload by : Ryan Jay

AGREE Reporting Checklist2016This checklist is intended to guide the reporting of clinical practice guidelines.CHECKLIST ITEM AND DESCRIPTIONReported on PageNumber/LineNumberREPORTING CRITERIADOMAIN 1: SCOPE AND PURPOSE1. OBJECTIVESReport the overall objective(s) of the guideline.The expected health benefits from the guidelineare to be specific to the clinical problem orhealth topic.Health intent(s) (i.e., prevention, screening, diagnosis, treatment, etc.)Expected benefit(s) or outcome(s)Target(s) (e.g., patient population, society)2. QUESTIONSReport the health question(s) coveredby the guideline, particularly for the keyrecommendations.Target populationIntervention(s) or exposure(s)Comparisons (if appropriate)Outcome(s)Health care setting or context3. POPULATIONDescribe the population (i.e., patients, public,etc.) to whom the guideline is meant to apply.Target population, sex and ageClinical condition (if relevant)Severity/stage of disease (if relevant)Comorbidities (if relevant)Excluded populations (if relevant)DOMAIN 2: STAKEHOLDER INVOLVEMENT4. GROUP MEMBERSHIPReport all individuals who were involved inthe development process. This may includemembers of the steering group, the researchteam involved in selecting and reviewing/rating the evidence and individuals involved informulating the final recommendations.Name of participantDiscipline/content expertise (e.g., neurosurgeon, methodologist)Institution (e.g., St. Peter’s hospital)Geographical location (e.g., Seattle, WA)A description of the member’s role in the guideline development group5-1Reported onSection/Paragraph

5. TARGET POPULATION PREFERENCESAND VIEWSReport how the views and preferences of thetarget population were sought/considered andwhat the resulting outcomes were.Statement of type of strategy used to capture patients’/publics’ views and preferences(e.g., participation in the guideline development group, literature review of values andpreferences)Methods by which preferences and views were sought (e.g., evidence from literature,surveys, focus groups)Outcomes/information gathered on patient/public informationHow the information gathered was used to inform the guideline development processand/or formation of the recommendations6. TARGET USERSReport the target (or intended) users of theguideline.The intended guideline audience (e.g. specialists, family physicians, patients, clinicalor institutional leaders/administrators)How the guideline may be used by its target audience (e.g., to inform clinicaldecisions, to inform policy, to inform standards of care)DOMAIN 3: RIGOUR OF DEVELOPMENT7. SEARCH METHODSReport details of the strategy used to search forevidence.Named electronic database(s) or evidence source(s) where the search was performed(e.g., MEDLINE, EMBASE, PsychINFO, CINAHL)Time periods searched (e.g., January 1, 2004 to March 31, 2008)Search terms used (e.g., text words, indexing terms, subheadings)Full search strategy included (e.g., possibly located in appendix)8. EVIDENCE SELECTION CRITERIAReport the criteria used to select (i.e., includeand exclude) the evidence. Provide rationale,where appropriate.Target population (patient, public, etc.) characteristicsStudy designComparisons (if relevant)OutcomesLanguage (if relevant)Context (if relevant)9. STRENGTHS & LIMITATIONS OF THEEVIDENCEDescribe the strengths and limitations of theevidence. Consider from the perspective of theindividual studies and the body of evidenceaggregated across all the studies. Tools existthat can facilitate the reporting of this concept.Study design(s) included in body of evidenceStudy methodology limitations (sampling, blinding, allocation concealment, analyticalmethods)Appropriateness/relevance of primary and secondary outcomes consideredConsistency of results across studiesDirection of results across studiesMagnitude of benefit versus magnitude of harmApplicability to practice context5-2

10. FORMULATION OF RECOMMENDATIONSDescribe the methods used to formulate therecommendations and how final decisions werereached. Specify any areas of disagreement andthe methods used to resolve them.Recommendation development process (e.g., steps used in modified Delphitechnique, voting procedures that were considered)Outcomes of the recommendation development process (e.g., extent to whichconsensus was reached using modified Delphi technique, outcome of votingprocedures)How the process influenced the recommendations (e.g., results of Delphi techniqueinfluence final recommendation, alignment with recommendations and the final vote)11. CONSIDERATION OF BENEFITS ANDHARMSReport the health benefits, side effects, andrisks that were considered when formulating therecommendations.Supporting data and report of benefitsSupporting data and report of harms/side effects/risksReporting of the balance/trade-off between benefits and harms/side effects/risksRecommendations reflect considerations of both benefits and harms/side effects/risks12. LINK BETWEEN RECOMMENDATIONSAND EVIDENCEDescribe the explicit link between therecommendations and the evidence on whichthey are based.How the guideline development group linked and used the evidence to informrecommendationsLink between each recommendation and key evidence (text description and/orreference list)Link between recommendations and evidence summaries and/or evidence tables inthe results section of the guideline13. EXTERNAL REVIEWReport the methodology used to conduct theexternal review.Purpose and intent of the external review (e.g., to improve quality, gather feedback ondraft recommendations, assess applicability and feasibility, disseminate evidence)Methods taken to undertake the external review (e.g., rating scale, open-endedquestions)Description of the external reviewers (e.g., number, type of reviewers, affiliations)Outcomes/information gathered from the external review (e.g., summary of keyfindings)How the information gathered was used to inform the guideline development processand/or formation of the recommendations (e.g., guideline panel considered results ofreview in forming final recommendations)14. UPDATING PROCEDUREDescribe the procedure for updating theguideline.A statement that the guideline will be updatedExplicit time interval or explicit criteria to guide decisions about when an update willoccurMethodology for the updating procedure5-3

DOMAIN 4: CLARITY OF PRESENTATION15. SPECIFIC AND UNAMBIGUOUSRECOMMENDATIONSDescribe which options are appropriate in whichsituations and in which population groups, asinformed by the body of evidence.A statement of the recommended actionIntent or purpose of the recommended action (e.g., to improve quality of life, todecrease side effects)Relevant population (e.g., patients, public)Caveats or qualifying statements, if relevant (e.g., patients or conditions for whom therecommendations would not apply)If there is uncertainty about the best care option(s), the uncertainty should be stated inthe guideline16. MANAGEMENT OPTIONSDescribe the different options for managing thecondition or health issue.Description of management optionsPopulation or clinical situation most appropriate to each option17. IDENTIFIABLE KEY RECOMMENDATIONSPresent the key recommendations so that theyare easy to identify.Recommendations in a summarized box, typed in bold, underlined, or presented as flowcharts or algorithmsSpecific recommendations grouped together in one sectionDOMAIN 5: APPLICABILITY18. FACILITATORS AND BARRIERS TOAPPLICATIONDescribe the facilitators and barriers to theguideline’s application.Types of facilitators and barriers that were consideredMethods by which information regarding the facilitators and barriers to implementingrecommendations were sought (e.g., feedback from key stakeholders, pilot testing ofguidelines before widespread implementation)Information/description of the types of facilitators and barriers that emerged from theinquiry (e.g., practitioners have the skills to deliver the recommended care, sufficientequipment is not available to ensure all eligible members of the population receivemammography)How the information influenced the guideline development process and/or formationof the recommendations19. IMPLEMENTATION ADVICE/TOOLSProvide advice and/or tools on how therecommendations can be applied in practice.Additional materials to support the implementation of the guideline in practice.For example:Guideline summary documentsLinks to check lists, algorithmsLinks to how-to manualsSolutions linked to barrier analysis (see Item 18)Tools to capitalize on guideline facilitators (see Item 18)Outcome of pilot test and lessons learned5-4

20. RESOURCE IMPLICATIONSDescribe any potential resource implications ofapplying the recommendations.Types of cost information that were considered (e.g., economic evaluations, drugacquisition costs)Methods by which the cost information was sought (e.g., a health economist was partof the guideline development panel, use of health technology assessments for specificdrugs, etc.)Information/description of the cost information that emerged from the inquiry (e.g.,specific drug acquisition costs per treatment course)How the information gathered was used to inform the guideline development processand/or formation of the recommendations21. MONITORING/ AUDITING CRITERIAProvide monitoring and/or auditing criteriato measure the application of guidelinerecommendations.Criteria to assess guideline implementation or adherence to recommendationsCriteria for assessing impact of implementing the recommendationsAdvice on the frequency and interval of measurementOperational definitions of how the criteria should be measuredDOMAIN 6: EDITORIAL INDEPENDENCE22. FUNDING BODYReport the funding body’s influence on thecontent of the guideline.The name of the funding body or source of funding (or explicit statement of nofunding)A statement that the funding body did not influence the content of the guideline23. COMPETING INTERESTSProvide an explicit statement that all groupmembers have declared whether they have anycompeting interests.Types of competing interests consideredMethods by which potential competing interests were soughtA description of the competing interestsHow the competing interests influenced the guideline process and development ofrecommendationsFrom: Brouwers MC, Kerkvliet K, Spithoff K, on behalf of the AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practiceguidelines. BMJ 2016;352:i1152. doi: 10.1136/bmj.i1152.For more information about the AGREE Reporting Checklist, please visit the AGREE Enterprise website at leave this space alone as it will be supplemented by the editorial office when needed.5-5Updated on April 13, 2020

AGREE Reporting Checklist 2016 This checklist is intended to guide the reporting of clinical practice guidelines. CHECKLIST ITEM AND DESCRIPTION REPORTING CRITERIA Reported on Page Number/Line Number Reported on Section/Paragraph DOMAIN 1: SCOPE AND PURPOSE 1. OBJ

Related Documents:

Manager Opening Checklist Line Check Prep Checklist Station Setup Bar Opening Checklist Closing Checklist Host Opening/Closing Checklist Multi‐unit Inspections Checklist Periodic Maintenance Checklist Permits & License Review Staff Reviews/Evaluations

Chemistry and Toxicology Checklist 07.11.2011 INTRODUCTION This Checklist is intended for comprehensive clinical chemistry testing, including blood gas analysis and toxicology. An inspection of a laboratory section, or department will include the discipline-specific checklist(s), the Laboratory General Checklist, and the All Common Checklist (COM).

That necessitated a revision of the audit checklist. The attached audit checklist replaces the checklist developed in May 1992. The checklist covers all the evaluation components of the previous checklist, but it also looks at other areas including a program's environmental effectiveness and its use of pollution-prevention measures. PURPOSE

Checklist für Diamond DA40 NG . Edition #: 17.3 Edition date: 15.04.2017. Please observe: The file you are receiving hereby combines all three sections of the checklist: Normal Checklist, Emergency Checklist and Abnormal Checklist. All pages of a new edition will have the same new "edition #" and "edition date", even if

Checklist für Diamond DA40 TDI G1000 . Edition #: 17.1 Edition date: 15.04.2017. Please observe: The file you are receiving hereby combines all three sections of the checklist: Normal Checklist, Emergency Checklist and Abnormal Checklist. All pages of a new edition will have the same new "edition #" and "edition date", even if

In the 26 years since 有iley publìshed Organic 1于ze Disconnection Approach 色y Stuart Warren,由自approach to the learning of synthesis has become while the book Ìtself is now dated in content and appearance' In 唱Tiley published Organic and Control by Paul Wyatt and Stuart 轧Tarren. Thís muc如柱。okís as a

Financial Reporting Checklist for North Carolina Counties . The checklist below is provided as a supplement to other audit programs and checklists that already address compliance with generally accepted accounting principles or federal programs. This checklist addresses issues within t

EDUQAS A LEVEL - COMPONENT 1 BUSINESS OPPORTUNITIES AND FUNCTIONS SUMMER 2018 MARK SCHEME SECTION A Q. Total 1 Give one example of a business using batch production and describe two benefits of this method of production. Award 1 mark for an appropriate example. AO1: 1 mark Indicative content: A baker making loaves of bread; a clothing manufacturer making batches of a particular garment; a .